Table 2. Clinical Outcomes of Patients With eGFR Less Than 30 mL/min/1.73 m2 at Time of Randomizationa.
| Variable | Remdesivir (n = 34) | Standard care (n = 25) | Difference in means (95% CI) |
|---|---|---|---|
| Hospital death, No. (%), unadjusted | 13 (40.6) | 13 (52.0) | RR, 0.78 (0.41 to 1.49) |
| New mechanical ventilation in those not ventilated at baseline, No. (%) | 4 (14.8) | 6 (26.1) | RR, 0.57 (0.15 to 1.80) |
| Total length of stay, d | |||
| Mean (SD) | 23.1 (20.5) | 21.6 (28.8) | 1.5 (–11.5 to 14.6) |
| Median (IQR) | 16.5 (10-29.5) | 11 (6-25) | NA |
| Day 5 creatinine, mg/dLb | |||
| Mean (SD) | 2.83 (2.15) | 4.12 (2.41) | –1.29 (–2.66 to 0.09) |
| Median (IQR) | 1.80 (1.32-3.40) | 3.47 (2.02-5.99) | NA |
| Day 5 eGFR, mL/min/1.73 m2b | |||
| Mean (SD) | 31.2 (19.2) | 20.5 (13.9) | 10.7 (0.20 to 21.2) |
| Median (IQR) | 29.2 (14.2-45) | 16.5 (8.5-30.9) | NA |
| ANCOVA for change in eGFR | –0.26 (–7.95 to 7.42) | ||
| Day 5 ALTc | |||
| Mean (SD) | 40.8 (36.4) | 91.9 (187) | –51.1 (–177.2 to 75.0) |
| Median (IQR) | 32.5 (15-47) | 31 (22-52) | NA |
| New dialysis in those not receiving dialysis at baseline, No. (%) | 5 (20.0) | 4 (21.1) | RR, 0.95 (0.25 to 3.56) |
| Any adverse event, No. (%) | 3 (8.8) | 6 (24.0) | RR, 0.37 (0.05 to 1.33) |
Abbreviations: ALT, alanine aminotransferase; ANCOVA, analysis of covariance; eGFR, estimated glomerular filtration rate; NA, not applicable; RR, relative risk.
SI conversion: To convert ALT to microkatals per liter, multiply by 0.0167; creatinine to micromoles per liter, 88.4.
a
Percentages reported for those with available outcome.
b
Available in 45 patients.
c
Available in 31 patients.